Archive for the ‘journal of clinical investigation’ Category
The timing was tight, but Sergio Gonzalez had done it. Gonzalez, a postdoctoral researcher at the Institute for Neurosciences of Montpellier (INSERM) in France, had a paper accepted in a top journal by the end of 2015, just in time to apply for a small number of highly sought-after permanent research positions that open up in France each year.
If Gonzalez had missed the January deadline for this system of advancement, known as concours, he would have had to wait until the following cycle to apply.
Once his paper was accepted by the Journal of Clinical Investigation, Gonzalez could breathe a sigh of relief. He began being invited to interviews. But then, a comment showed up at PubPeer.
Researchers at Columbia University have retracted a 2013 paper in The Journal of Clinical Investigation, after uncovering abnormalities in the stem cell lines that undermined the conclusions in the paper.
Last year, corresponding author Dieter Egli discovered he could not reproduce key data in the 2013 paper because almost all the cell lines first author Haiqing Hua used contained abnormalities, casting doubt on the overall findings. When Egli reached out to Hua for answers, Hua could not explain the abnormalities. As a result, Hua and Egli agreed the paper should be retracted.
Since some of the details of how the paper ended up relying on abnormal cells remain unclear, the university confirmed to us that it is investigating the matter.
Here’s the retraction notice for “iPSC-derived β cells model diabetes due to glucokinase deficiency,” cited 42 times: Read the rest of this entry »
Both papers — which are more than a decade old — were pulled in The Journal of Clinical Investigation on November 1 by their respective corresponding authors.
One paper’s last author told us it was difficult to identify how the duplications occurred since the study took place so long ago, but added that multiple experiments had corroborated the results.
We’ve found another retraction for Erin Potts-Kant, a former researcher at Duke, bringing her total to 15.
Yesterday we reported on two new retractions for Potts-Kant in PLoS ONE, which earned her a spot in the top 30 on our leaderboard. As with the others, the latest paper, in the Journal of Clinical Investigation, is marred by “unreliable” data.
Retraction number nine, by The Journal of Clinical Investigation, is for duplicating data from another publication — which has also faced questions on PubPeer about image manipulation, along with many other papers by Fusco.
The retraction note for “The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells” explains that the journal is pulling the paper even though the authors claim that they can reproduce the data:
The correction changes details from the name of an author to figure legends, and adds entire supplemental figures.
Shortly after the paper’s publication on April 20th, commenters on PubPeer pointed out duplications in multiple figure panels.
Last month, the journal issued an extensive correction note for “Immunosurveillance and therapy of multiple myeloma are CD226 dependent,” which, in part, tries to explain the multiple duplications.
It starts out noting a typo:
Take a look at figure one to the right and see if you can spot all the doubles.
Click here for a more zoomable image.
Here’s the notice for “Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients,” a 2011 paper by researchers at Johns Hopkins and Imperial College: Read the rest of this entry »
A researcher who admitted in 2012 to “intentional and systematic manipulation” of data and had two papers retracted has been banned from funding by the German Research Foundation (DFG).
Dennis Rottländer, who will also be returning prize money he was awarded for the research, worked in Uta C. Hoppe’s lab at the University of Cologne. Hoppe, now at University Hospital Salzburg, remains under investigation, according to a statement from the DFG.
Excerpt: Read the rest of this entry »